EGFR and neoplasm: Overexpression of ERBB1, which is associated with increased tumor size and poor outcome, occurs in 15 to 30% of breast cancers [99]; ERBB1 is also overexpressed in anywhere from 13 to 76% of triple negative breast cancers [100–102].